Dipeptidyl peptidase IV inhibitory activity of Commiphora mukul monotherapy and combination therapy (with Metformin) attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analysis
Abstract
Objectives: The marketed synthetic Dipeptidyl peptidase-IV (DPP-IV) inhibitors are expensive antidiabetic drugs and have been reported to cause unacceptable adverse effects. In this scenario research to develop novel DPP-IV inhibitors from alternative sources is the need of the hour. Commiphora mukul, a medicinal plant with antidiabetic and cardioprotective activities may represent a natural DPP-IV inhibitor, the DPP-IV inhibitory activity of which may translate into demonstrable therapeutic benefits in setting of diabetes with cardiovascular co-morbidities. Materials and methods: The DPP-IV inhibitory, antidiabetic and cardioprotective effects of Commiphora mukul monotherapy and combination therapy (with Metformin) was evaluated in the experimental model of myocardial infarction co-existing with diabetes. To determine the active principle of Commiphora mukul responsible for DPP-IV inhibitory activity, the crystal structure of DPP-IV was considered as receptor which was docked against Gluggusterone E, Gluggusterone Z, Sitagliptin and Vildagliptin. Results: Commiphora mukul monotherapy as well as in combination therapy (with Metformin) demonstrated significant DPP-IV inhibitory, antidiabetic and cardioprotective effects in the experimental model of myocardial infarction co-existing with diabetes. Cardioprotective effects of Commiphora mukul treatment may be attributed to several mechanisms (DPP-IV inhibition, hypolipidemic, reduced atherogenic potential, anti-thrombotic…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.